These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263 [TBL] [Abstract][Full Text] [Related]
4. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes. Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664 [TBL] [Abstract][Full Text] [Related]
5. Searching for prognostic biomarkers for small renal masses in the urinary proteome. Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112 [TBL] [Abstract][Full Text] [Related]
6. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients. Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454 [TBL] [Abstract][Full Text] [Related]
7. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988 [TBL] [Abstract][Full Text] [Related]
8. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842 [TBL] [Abstract][Full Text] [Related]
9. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-30a-5p Outeiro-Pinho G; Barros-Silva D; Aznar E; Sousa AI; Vieira-Coimbra M; Oliveira J; Gonçalves CS; Costa BM; Junker K; Henrique R; Jerónimo C J Exp Clin Cancer Res; 2020 Jun; 39(1):98. PubMed ID: 32487203 [TBL] [Abstract][Full Text] [Related]
11. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976 [TBL] [Abstract][Full Text] [Related]
12. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Papale M; Vocino G; Lucarelli G; Rutigliano M; Gigante M; Rocchetti MT; Pesce F; Sanguedolce F; Bufo P; Battaglia M; Stallone G; Grandaliano G; Carrieri G; Gesualdo L; Ranieri E Oncotarget; 2017 Jun; 8(25):40412-40424. PubMed ID: 28418894 [TBL] [Abstract][Full Text] [Related]
13. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000 [TBL] [Abstract][Full Text] [Related]
14. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics. Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624 [TBL] [Abstract][Full Text] [Related]
16. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. Kim K; Taylor SL; Ganti S; Guo L; Osier MV; Weiss RH OMICS; 2011 May; 15(5):293-303. PubMed ID: 21348635 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025 [TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778 [TBL] [Abstract][Full Text] [Related]